NTRA trades 14.3% above Wall Street's consensus target of $335.07.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NTRA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 28 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 23, 2026, Natera, Inc. (NTRA) has a Wall Street consensus price target of $335.07, based on estimates from 28 covering analysts. With the stock currently trading at $390.90, this represents a potential downside of -14.3%. The company has a market capitalization of $55.98B.
Analyst price targets range from a low of $245.00 to a high of $435.00, representing a 57% spread in expectations. The median target of $348.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 25 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NTRA trades at a trailing P/E of -257.2x. Analysts expect EPS to grow -0.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXASExact Sciences Corporation | $20.0B | $104.91 | $92.95 | -11.4% | Buy | 582.8x | 41 |
 ILMNIllumina, Inc. | $37.4B | $247.46 | $210.67 | -14.9% | Buy | 46.2x | 50 |
 CGENCompugen Ltd. | $235M | $2.49 | $5.00 | +100.8% | Buy | — | 14 |
 MYRGMYR Group Inc. | $4.5B | $289.05 | $444.40 | +53.7% | Hold | 23.7x | 21 |
 PACBPacific Biosciences of California, Inc. | $457M | $1.47 | $1.18 | -19.7% | Buy | — | 18 |
 PRMEPrime Medicine, Inc. | $639M | $3.54 | $7.50 | +111.9% | Buy | — | 10 |
 CDNACareDx, Inc | $2.9B | $56.49 | $58.75 | +4.0% | Buy | 46.9x | 13 |
 TMOThermo Fisher Scientific Inc. | $244.7B | $658.52 | $623.36 | -5.3% | Buy | 26.2x | 43 |
 DHRDanaher Corporation | $155.4B | $221.12 | $223.77 | +1.2% | Buy | 26.0x | 43 |
 AAgilent Technologies, Inc. | $47.2B | $167.25 | $170.00 | +1.6% | Buy | 27.0x | 41 |
Quick answers to the most common questions about buying NTRA stock.
NTRA's consensus price target is $335.07, -14.3% below the current price of $390.9. The 28 analysts tracking NTRA see downside risk at present valuations.
NTRA has a consensus rating of "Buy" based on 28 Wall Street analysts. The rating breakdown is predominantly bullish, with 25 Buy/Strong Buy ratings. The consensus 12-month price target of $335.07 implies -14.3% downside from current levels.
NTRA's current price is $390.9 with a consensus target of $335.07 (-14.3% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $435 for NTRA, while the most conservative target is $245. The consensus of $335.07 represents the median expectation. These targets typically reflect 12-month expectations.
NTRA is heavily covered by Wall Street, with 28 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 25 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NTRA stock forecast based on 28 Wall Street analysts shows a consensus price target of $335.07, with estimates ranging from $245 (bear case) to $435 (bull case). The median consensus rating is "Buy".
Analysts are cautious on NTRA, with 0 Sell ratings and a price target of $335.07 (-14.3% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NTRA analyst price targets range from $245 to $435, a 57% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $335.07 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.